<DOC>
	<DOC>NCT00954746</DOC>
	<brief_summary>The purpose of study AUX-CC-860 is to assess the durability of response of the AA4500 treatment regimen. This study will also evaluate long-term safety and progression of disease in joints.</brief_summary>
	<brief_title>Longterm Observational Study in Subjects Treated With AA4500 in AUX-CC-854, 856, 857, 858 &amp; 859</brief_title>
	<detailed_description>Phase 3 non-treatment study in which Year 2 to Year 5 year follow-up of subjects who received AA4500 in the 9-month open-label studies (AUX-CC-854 and AUX-CC-856) or the 12-month double-blind with open-label extension studies (AUX-CC-857/AUX-CC-858 and AUX-CC-859). After completion of one of the above mentioned studies, subjects are enrolled and followed once a calendar year for 4 consecutive years with at least 6 months between consecutive visits.</detailed_description>
	<mesh_term>Dupuytren Contracture</mesh_term>
	<criteria>To be eligible for this study a subject had to: Have received at least one injection of AA4500 in one of the Auxilium sponsored studies (AUXCC854, AUXCC856, Studies AUXCC857/AUXCC858, or AUXCC859) and have at least one fixedflexion contracture measurement after treatment with AA4500 Be able and willing to comply with the yearly assessments outlined in the protocol, as determined by the investigator Voluntarily sign and date an informed consent agreement approved by the Institutional Review Board/Independent Ethics Committee (IRB/IEC)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Advanced Dupuytren's Disease</keyword>
	<keyword>Muscular Diseases</keyword>
	<keyword>Musculoskeletal Diseases</keyword>
	<keyword>Contracture Joint Diseases</keyword>
	<keyword>Connective Tissue Diseases</keyword>
	<keyword>Dupuytren's Contracture</keyword>
</DOC>